R 1164Alternative Names: R1164
Latest Information Update: 31 Aug 2006
At a glance
- Originator Roche
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 31 Aug 2006 Discontinued - Phase-I for Osteoporosis in Europe (unspecified route)
- 01 May 2002 Phase-I clinical trials in Osteoporosis in Europe (unspecified route)